liblomycin ( lbm ) , a novel bleomycin analogue , and bleomycin a2 ( blm a2 ) were compared with respect to their relative potential to inhibit growth in a human head and neck squamous carcinoma cell line and to produce dna damage within cellular dna and nuclei dna and against isolated naked dna .
C0007634
cellular
C0007610
nuclei